908 Devices (NASDAQ:MASS) Receives “Sell (E+)” Rating from Weiss Ratings

Weiss Ratings reiterated their sell (e+) rating on shares of 908 Devices (NASDAQ:MASS) in a report published on Wednesday,Weiss Ratings reports.

Other research analysts have also issued research reports about the stock. Leerink Partners reiterated a “market perform” rating and set a $4.00 price objective (down previously from $12.00) on shares of 908 Devices in a research note on Wednesday, November 13th. Stifel Nicolaus lowered their price objective on shares of 908 Devices from $17.00 to $6.00 and set a “buy” rating on the stock in a research note on Wednesday, November 13th. Stephens reiterated an “overweight” rating and set a $6.00 price objective on shares of 908 Devices in a research note on Wednesday, January 15th. Finally, Leerink Partnrs lowered shares of 908 Devices from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, November 13th. Two investment analysts have rated the stock with a hold rating and two have issued a buy rating to the stock. According to data from MarketBeat, 908 Devices currently has a consensus rating of “Moderate Buy” and a consensus price target of $5.33.

908 Devices Trading Down 3.3 %

Shares of NASDAQ:MASS opened at $2.66 on Wednesday. The firm’s 50 day moving average is $2.37 and its two-hundred day moving average is $3.06. 908 Devices has a 52 week low of $1.81 and a 52 week high of $7.91. The firm has a market capitalization of $92.62 million, a P/E ratio of -1.50 and a beta of 0.99.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the company. Two Sigma Advisers LP acquired a new position in shares of 908 Devices during the fourth quarter valued at about $30,000. Prudential Financial Inc. acquired a new position in shares of 908 Devices during the fourth quarter valued at about $34,000. SG Americas Securities LLC acquired a new position in shares of 908 Devices during the third quarter valued at about $36,000. Occudo Quantitative Strategies LP acquired a new position in shares of 908 Devices during the fourth quarter valued at about $36,000. Finally, Two Sigma Investments LP bought a new stake in 908 Devices in the fourth quarter valued at about $42,000. Institutional investors and hedge funds own 88.06% of the company’s stock.

About 908 Devices

908 Devices Inc, a commercial-stage technology company, provides various purpose-built handheld and desktop mass spectrometry devices to interrogate unknown and invisible materials in life sciences research, bioprocessing, pharma/biopharma, forensics, and adjacent markets. The company's products include MX908, a handheld, battery-powered, and Mass Spec device that is designed for rapid analysis of solid, liquid, vapor, and aerosol materials of unknown identity; Rebel, a small desktop analyzer that provides real-time information on the extracellular environment in bioprocesses; and Maverick, an optical in-line analyzer that offers real-time monitoring and control of multiple bioprocess parameters, including glucose, lactate, and total biomass in mammalian cell cultures, as well as provides process fingerprint data to support large-scale efforts in predictive bioprocess modeling.